Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
9.52
-0.59 (-5.84%)
At close: Feb 21, 2025, 4:00 PM
9.83
+0.31 (3.26%)
After-hours: Feb 21, 2025, 4:35 PM EST
Company Description
Immunome, Inc., a biotechnology company, develops targeted cancer therapies.
The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Clay Siegall |
Contact Details
Address: 18702 N. Creek Parkway, Suite 100 Bothell, Washington 98011 United States | |
| Phone | 610 321 3700 |
| Website | immunome.com |
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| Employer ID | 77-0694340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Clay B. Siegall Ph.D. | President, Chief Executive Officer and Chairman |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
| Max Rosett | Executive Vice President of Operations, Principal Accounting and Financial Officer and Chief Financial Officer |
| Dr. Philip Tsai | Chief Technical Officer |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
| Bruce Turner M.D., Ph.D. | Chief Strategy Officer |
| Kinney Horn | Chief Business Officer |
| Roee Shahar | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | SCHEDULE 13D/A | Filing |
| Feb 3, 2025 | SCHEDULE 13G | Filing |
| Jan 30, 2025 | SCHEDULE 13G/A | Filing |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 424B5 | Filing |
| Jan 29, 2025 | 424B5 | Filing |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Nov 22, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |